Stockreport

Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Bolt Biotherapeutics, Inc.  (BOLT) 
PDF Presentation of preclinical data supporting the selection of BDC-2034, an ISAC targeting CEA, as Bolt Biotherapeutics’ second Boltbody™ ISAC development candidateDemonst [Read more]